PTC
TXMD icon

Private Trust Company’s TherapeuticsMD TXMD Stock Holding History

Private Trust Company’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16
Closed -$66 – 2383
2023
Q2 		$66 Hold
16
– – ﹤0.01% 2282
2023
Q1 		$60 Buy
+16
New +$77 ﹤0.01% 2262
2022
Q4 		– Sell
-16
Closed – – 2272
2022
Q3 		$0 Buy
+16
New +$130 ﹤0.01% 2199

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Trust Company's TXMD Position: Q3 2023 in Review

Private Trust Company sold out of TherapeuticsMD (TXMD) in Q3 2023, closing a stake of 16 shares — an estimated $66 sold.

Private Trust Company first reported a position in TXMD in Q3 2022 and held it in 3 quarters. The position peaked at $66 in Q2 2023. 36 funds tracked by Wall St. Rank hold TXMD as of Q3 2023.

  • Private Trust Company reported no remaining TherapeuticsMD position as of Q3 2023 after selling out during the quarter.
  • Private Trust Company sold 16 TherapeuticsMD shares in Q3 2023, an estimated $66.
  • Private Trust Company first reported a position in TherapeuticsMD in Q3 2022 and held it in 3 quarters.
  • Private Trust Company's TherapeuticsMD position peaked at $66 in Q2 2023.
  • 36 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2023.

Based on Private Trust Company's 13F filing for Q3 2023, filed 18 Oct 2023.